醫(yī)藥創(chuàng)新是推動(dòng)產(chǎn)業(yè)升級的核心動(dòng)力。多數(shù)國家加強(qiáng)醫(yī)藥創(chuàng)新頂層設(shè)計(jì)、強(qiáng)化資金支持、促進(jìn)國內(nèi)產(chǎn)學(xué)研合作、加強(qiáng)國際合作、健全和完善創(chuàng)新藥價(jià)格支付機(jī)制和創(chuàng)新回報(bào)機(jī)制等，為本國醫(yī)藥創(chuàng)新和產(chǎn)業(yè)發(fā)展提供了強(qiáng)有力的制度保障。梳理了美國、歐盟、英國、日本在醫(yī)藥創(chuàng)新方面的政策和措施，提出了優(yōu)化我國醫(yī)藥創(chuàng)新的策略，以期為我國醫(yī)藥創(chuàng)新提供借鑒和參考。

Medical innovation is the core driving force for promoting industrial upgrading. Most countries have provided strong institutional guarantees for their own pharmaceutical innovation and industrial development through policies such as strengthening top-level design of pharmaceutical innovation, enhancing financial support, promoting domestic industry university research cooperation, strengthening international cooperation, and improving innovative drug pricing payment mechanisms. This article summarizes the policies and measures of the United States, the European Union, the United Kingdom, and Japan in the field of pharmaceutical innovation, and proposes strategies to optimize China's pharmaceutical innovation, in order to provide reference and guidance for China's pharmaceutical innovation.

R951